Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2

Chao, Angel; Lin, Chung-Tzu; Lee, Y. S.; Tsai, Chia-Lung; Wei, Pei-Cih; Hsueh, Swei; Wu, Tingqing; Wang, C. J.; Wang, T. H.; Lai, Chyong‐Huey

doi:10.1038/onc.2011.269

Cited by 132 publications

(106 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is supported by several studies highlighting a tumor suppressor role for miR-187. In ovarian cancer, decreased miR-187 is associated with poorer survival and was demonstrated to regulate cancer progression via its negative regulation of disabled homolog-2, which plays an important role in epithelial-mesenchymal transition (31). This is also supported in clear cell renal cell carcinoma, where decreased miR-187 expression is associated with poorer survival (20).…”

Section: C3 Is Altered In Pretreatment Eac Tumors From Nonresponderssupporting

confidence: 53%

Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma

Lynam‐Lennon

Bibby

Mongan

et al. 2016

Mol Med

View full text Add to dashboard Cite

Section: C3 Is Altered In Pretreatment Eac Tumors From Nonresponderssupporting

confidence: 53%

Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma

Lynam‐Lennon

Bibby

Mongan

et al. 2016

Mol Med

View full text Add to dashboard Cite

“…In a recent study, miR-187 was shown to be instrumental in the regulation of ovarian cancer progression through the targeting of disabled homolog 2 (Dab2), and was significantly associated with increased OS and RFS in a cohort of patients with the disease (n ¼ 176; ref. 41). In breast cancer, Blenkiron and colleagues have observed that miR-187 is expressed at higher levels in ER-negative versus -positive tumors and seems to be over-represented in HER2-positive cancers (42), whereas Hui and colleagues note that the expression of the miRNA is more than 2.6-fold increased in breast cancer versus normal tissue (43).…”

Section: Discussionmentioning

confidence: 99%

miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive PotentialIn Vitro

Mulrane

Madden

Brennan

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Here, we describe an integrated bioinformatics, functional analysis, and translational pathology approach to identify novel miRNAs involved in breast cancer progression.Experimental Design: Coinertia analysis (CIA) was used to combine a database of predicted miRNA target sites and gene expression data. Using two independent breast cancer cohorts, CIA was combined with correspondence analysis and between group analysis to produce a ranked list of miRNAs associated with disease progression. Ectopic expression studies were carried out in MCF7 cells and miRNA expression evaluated in two additional cohorts of patients with breast cancer by in situ hybridization on tissue microarrays.Results: CIA identified miR-187 as a key miRNA associated with poor outcome in breast cancer. Ectopic expression of miR-187 in breast cancer cells resulted in a more aggressive phenotype. In a test cohort (n ¼ 117), high expression of miR-187 was associated with a trend toward reduced breast cancer-specific survival (BCSS; P ¼ 0.058), and a significant association with reduced BCSS in lymph node-positive patients (P ¼ 0.036). In a validation cohort (n ¼ 470), high miR-187 was significantly associated with reduced BCSS in the entire cohort (P ¼ 0.021) and in lymph node-positive patients (P ¼ 0.012). Multivariate Cox regression analysis revealed that miR-187 is an independent prognostic factor in both cohorts [cohort 1: HR, 7.37; 95% confidence interval (CI), 2.05-26.51; P ¼ 0.002; cohort 2: HR, 2.80; 95% CI, 1.52-5.16; P ¼ 0.001] and in lymph node-positive patients in both cohorts (cohort 1: HR, 13.74; 95% CI, 2.62-72.03; P ¼ 0.002; cohort 2: HR, 2.77; 95% CI, 1.32-5.81; P ¼ 0.007).Conclusions: miR-187 expression in breast cancer leads to a more aggressive, invasive phenotype and acts as an independent predictor of outcome. Clin Cancer Res; 18(24); 6702-13. Ó2012 AACR.

show abstract

“…Studies have implicated miR-187 activity in the development of various types of tumors (5,17,18); however, its role in DLBCL has not yet been established.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6

2016

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRs) are endogenous non-coding RNAs that serve key functions in a wide range of biological processes, including cell growth, development, apoptosis and carcinogenesis. However, the association between miR-187 and B-cell lymphoma 6 (BCL6) has yet to be fully investigated in lymphoma cell apoptosis. The present study hypothesized that a post-translational mechanism may exist for BCL6 expression, which is regulated by miR-187 in lymphoma cells. The present study demonstrated that the expression of miR-187 in diffuse large B-cell lymphoma (DLBCL) cells was significantly decreased, and its expression was negatively correlated with BCL6 expression. It was also observed that miR-187 directly binds to the 3'-untranslated region of BCL6 mRNA and subsequently suppresses the expression of BCL6. Additionally, the induced expression of miR-187 significantly promoted DLBCL cell apoptosis in vitro. The drug sensitivity of human DLBCL SUDHL2 cells was increased following induction of miR-187 overexpression via an miR-187 mimic. In conclusion, the results of the present study suggest that the modulation of miR-187 expression in DLBCL cells may improve the sensitivity of chemotherapy through BCL6 targeting.

show abstract

Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2

Cited by 132 publications

References 38 publications

Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma

Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma

miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive PotentialIn Vitro

MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6

Contact Info

Product

Resources

About